Machine learning for MRI radiomics: a study predicting tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma

被引:11
作者
Bian, Yun [1 ]
Liu, Yan Fang [2 ]
Jiang, Hui [2 ]
Meng, Yinghao [1 ]
Liu, Fang [1 ]
Cao, Kai [1 ]
Zhang, Hao [1 ]
Fang, Xu [1 ]
Li, Jing [1 ]
Yu, Jieyu [1 ]
Feng, Xiaochen [1 ]
Li, Qi [1 ]
Wang, Li [1 ]
Lu, Jianping [1 ]
Shao, Chengwei [1 ,3 ]
机构
[1] Navy Med Univ, Changhai Hosp, Dept Radiol, Shanghai 200434, Peoples R China
[2] Navy Med Univ, Changhai Hosp, Dept Pathol, Shanghai, Peoples R China
[3] Changhai Hosp, Dept Radiol, 168 Changhai Rd, Shanghai 200433, Peoples R China
基金
美国国家科学基金会;
关键词
Pancreatic neoplasm; Carcinoma; CD4 positive T lymphocytes; CD8 positive T lymphocytes; Magnetic resonance imaging; Radiomics; Tumor microenvironment; NIVOLUMAB; CANCER; SURVIVAL; IMMUNOTHERAPY; GEMCITABINE; PROGNOSIS;
D O I
10.1007/s00261-021-03159-9
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To develop and validate a machine learning classifier based on magnetic resonance imaging (MRI), for the preoperative prediction of tumor-infiltrating lymphocytes (TILs) in patients with pancreatic ductal adenocarcinoma (PDAC). Materials and methods In this retrospective study, 156 patients with PDAC underwent MR scan and surgical resection. The expression of CD4, CD8 and CD20 was detected and quantified using immunohistochemistry, and TILs score was achieved by Cox regression model. All patients were divided into TILs score-low and TILs score-high groups. The least absolute shrinkage and selection operator method and the extreme gradient boosting (XGBoost) were used to select the features and to construct a prediction model. The performance of the models was assessed using the training cohort (116 patients) and the validation cohort (40 patients), and decision curve analysis (DCA) was applied for clinical use. Results The XGBoost prediction model showed good discrimination in the training (AUC 0.86; 95% CI 0.79-0.93) and validation sets (AUC 0.79; 95% CI 0.64-0.93). The sensitivity, specificity, and accuracy for the training set were 86.67%, 75.00%, and 0.81, respectively, whereas those for the validation set were 84.21%, 66.67%, and 0.75, respectively. Decision curve analysis indicated the clinical usefulness of the XGBoost classifier. Conclusion The model constructed by XGBoost could predict PDAC TILs and may aid clinical decision making for immune therapy.
引用
收藏
页码:4800 / 4816
页数:17
相关论文
共 36 条
  • [1] Amin MB, 2017, AJCC cancer staging manual, Veighth
  • [2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [3] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
    Brahmer, Julie R.
    Tykodi, Scott S.
    Chow, Laura Q. M.
    Hwu, Wen-Jen
    Topalian, Suzanne L.
    Hwu, Patrick
    Drake, Charles G.
    Camacho, Luis H.
    Kauh, John
    Odunsi, Kunle
    Pitot, Henry C.
    Hamid, Omid
    Bhatia, Shailender
    Martins, Renato
    Eaton, Keith
    Chen, Shuming
    Salay, Theresa M.
    Alaparthy, Suresh
    Grosso, Joseph F.
    Korman, Alan J.
    Parker, Susan M.
    Agrawal, Shruti
    Goldberg, Stacie M.
    Pardoll, Drew M.
    Gupta, Ashok
    Wigginton, Jon M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) : 2455 - 2465
  • [4] Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer
    Braman, Nathaniel
    Prasanna, Prateek
    Whitney, Jon
    Singh, Salendra
    Beig, Niha
    Etesami, Maryam
    Bates, David D. B.
    Gallagher, Katherine
    Bloch, B. Nicolas
    Vulchi, Manasa
    Turk, Paulette
    Bera, Kaustav
    Abraham, Jame
    Sikov, William M.
    Somlo, George
    Harris, Lyndsay N.
    Gilmore, Hannah
    Plecha, Donna
    Varadan, Vinay
    Madabhushi, Anant
    [J]. JAMA NETWORK OPEN, 2019, 2 (04)
  • [5] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
    Burris, HA
    Moore, MJ
    Andersen, J
    Green, MR
    Rothenberg, ML
    Madiano, MR
    Cripps, MC
    Portenoy, RK
    Storniolo, AM
    Tarassoff, P
    Nelson, R
    Dorr, FA
    Stephens, CD
    VanHoff, DD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2403 - 2413
  • [6] CAMP RL, 2004, CLIN CANCER RES, V10, P7252, DOI [DOI 10.1158/1078-0432.CCR-04-0713, 10.1158/1078-0432.CCR-04-0713]
  • [7] Collins GS, 2015, BMJ-BRIT MED J, V350, DOI [10.1136/bmj.g7594, 10.1111/1471-0528.13244]
  • [8] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Conroy, Thierry
    Desseigne, Francoise
    Ychou, Marc
    Bouche, Olivier
    Guimbaud, Rosine
    Becouarn, Yves
    Adenis, Antoine
    Raoul, Jean-Luc
    Gourgou-Bourgade, Sophie
    de la Fouchardiere, Christelle
    Bennouna, Jaafar
    Bachet, Jean-Baptiste
    Khemissa-Akouz, Faiza
    Pere-Verge, Denis
    Delbaldo, Catherine
    Assenat, Eric
    Chauffert, Bruno
    Michel, Pierre
    Montoto-Grillot, Christine
    Ducreux, Michel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1817 - 1825
  • [9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [10] Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
    Emens, Leisha A.
    Ascierto, Paolo A.
    Darcy, Phillip K.
    Demaria, Sandra
    Eggermont, Alexander M. M.
    Redmond, William L.
    Seliger, Barbara
    Marincola, Francesco M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 81 : 116 - 129